Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance.
Autophagy is an ancient, intracellular degradative system which plays important roles in regulating protein homeostasis and which is essential for survival when cells are faced with metabolic stress. Increasing evidence suggests that autophagy also functions as a tumor suppressor mechanism that harnesses the growth and/or survival of cells as they transition towards a rapidly dividing malignant state. However, the impact of autophagy on cancer progression and on the efficacy of cancer therapeutics is controversial. In particular, although the induction of autophagy has been reported after treatment with a number of therapeutic agents, including imatinib, this response has variously been suggested to either impair or contribute to the effects of anticancer agents. More recent studies support the notion that autophagy compromises the efficacy of anticancer agents, where agents such as chloroquine (CQ) that impair autophagy augment the anticancer activity of histone deacetylase (HDAC) inhibitors and alkylating agents. Inhibition of autophagy is a particularly attractive strategy for the treatment of imatinib-refractory chronic myelogenous leukemia (CML) since a combination of CQ with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) compromises the survival of even BCR-ABL-T315I+ imatinib-resistant CML. Additional studies are clearly needed to establish the clinical utility of autophagy inhibitors and to identify patients most likely to benefit from this novel therapeutic approach.
Carew
Jennifer S
JS
The CTRC Institute for Drug Development, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
Nawrocki
Steffan T
ST
Giles
Francis J
FJ
Cleveland
John L
JL
Cancer Res. 2005 Sep 1;65(17):7832-9
16140952
J Cell Biol. 2005 May 9;169(3):425-34
15866887
Cell Death Differ. 2005 Nov;12 Suppl 2:1542-52
16247502
Nat Rev Mol Cell Biol. 2005 Jun;6(6):439-48
15928708
Cancer Res. 2001 Jan 15;61(2):439-44
11212227
Carcinogenesis. 1996 Aug;17(8):1595-607
8761415
Blood. 2007 Jul 1;110(1):313-22
17363733
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15077-82
14657337
J Exp Med. 2003 May 19;197(10):1323-34
12756268
J Clin Invest. 2007 Feb;117(2):326-36
17235397
Leukemia. 2007 May;21(5):936-42
17330103
J Clin Invest. 2008 Jan;118(1):79-88
18097482
Nat Clin Pract Oncol. 2005 Mar;2(3):150-7
16264908
Nature. 2004 Dec 23;432(7020):1032-6
15525940
J Clin Invest. 2003 Dec;112(12):1809-20
14638851
Science. 2000 Dec 1;290(5497):1717-21
11099404
Cancer Cell. 2002 Aug;2(2):117-25
12204532
Genomics. 1999 Jul 1;59(1):59-65
10395800
Cancer Res. 2003 May 1;63(9):2103-8
12727826
Cancer Res. 2006 Apr 1;66(7):3773-81
16585204
Cancer Res. 2005 Apr 15;65(8):3336-46
15833867
Nature. 1999 Dec 9;402(6762):672-6
10604474
Cancer Biol Ther. 2003 Sep-Oct;2(5):544-51
14614324
Cell. 2005 Jan 28;120(2):237-48
15680329
Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18030-5
15596714
N Engl J Med. 2006 Jun 15;354(24):2531-41
16775234
Proc Natl Acad Sci U S A. 2006 May 9;103(19):7444-9
16651519
Cancer Res. 2005 Apr 15;65(8):2993-5
15833821
N Engl J Med. 2006 Jun 15;354(24):2542-51
16775235
Nat Rev Cancer. 2007 Dec;7(12):961-7
17972889